Global CD47 (IAP) Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global CD47 (IAP) market size was valued at US$ million in 2023. With growing demand in downstream market, the CD47 (IAP) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global CD47 (IAP) market. CD47 (IAP) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of CD47 (IAP). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the CD47 (IAP) market.
Key Features:
The report on CD47 (IAP) market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the CD47 (IAP) market. It may include historical data, market segmentation by Type (e.g., CD47 Monoclonal Antibody, CD47 Double Antibody), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the CD47 (IAP) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the CD47 (IAP) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the CD47 (IAP) industry. This include advancements in CD47 (IAP) technology, CD47 (IAP) new entrants, CD47 (IAP) new investment, and other innovations that are shaping the future of CD47 (IAP).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the CD47 (IAP) market. It includes factors influencing customer ' purchasing decisions, preferences for CD47 (IAP) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the CD47 (IAP) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting CD47 (IAP) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the CD47 (IAP) market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the CD47 (IAP) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the CD47 (IAP) market.
Market Segmentation:
CD47 (IAP) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global CD47 (IAP) market size was valued at US$ million in 2023. With growing demand in downstream market, the CD47 (IAP) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global CD47 (IAP) market. CD47 (IAP) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of CD47 (IAP). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the CD47 (IAP) market.
Key Features:
The report on CD47 (IAP) market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the CD47 (IAP) market. It may include historical data, market segmentation by Type (e.g., CD47 Monoclonal Antibody, CD47 Double Antibody), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the CD47 (IAP) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the CD47 (IAP) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the CD47 (IAP) industry. This include advancements in CD47 (IAP) technology, CD47 (IAP) new entrants, CD47 (IAP) new investment, and other innovations that are shaping the future of CD47 (IAP).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the CD47 (IAP) market. It includes factors influencing customer ' purchasing decisions, preferences for CD47 (IAP) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the CD47 (IAP) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting CD47 (IAP) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the CD47 (IAP) market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the CD47 (IAP) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the CD47 (IAP) market.
Market Segmentation:
CD47 (IAP) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- CD47 Monoclonal Antibody
- CD47 Double Antibody
- CD47 Fusion Protein
- Solid Tumor
- Lymphoma
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Gilead
- Innovent Biologics
- Akeso, Inc
- Arch Oncology
- ImmuneOncia Therapeutics
- I-MAB
- Sorrento Therapeutics
- Zai Lab
- ImmuneOnco
- Hengrui
- Beijing Mab-works
- Hanxbio
- ALX Oncology
- Surface Oncology
- TG Therapeutics
- EpicentRx
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD47 (IAP) Market Size 2019-2030
2.1.2 CD47 (IAP) Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 CD47 (IAP) Segment by Type
2.2.1 CD47 Monoclonal Antibody
2.2.2 CD47 Double Antibody
2.2.3 CD47 Fusion Protein
2.3 CD47 (IAP) Market Size by Type
2.3.1 CD47 (IAP) Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global CD47 (IAP) Market Size Market Share by Type (2019-2024)
2.4 CD47 (IAP) Segment by Application
2.4.1 Solid Tumor
2.4.2 Lymphoma
2.4.3 Others
2.5 CD47 (IAP) Market Size by Application
2.5.1 CD47 (IAP) Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global CD47 (IAP) Market Size Market Share by Application (2019-2024)
3 CD47 (IAP) MARKET SIZE BY PLAYER
3.1 CD47 (IAP) Market Size Market Share by Players
3.1.1 Global CD47 (IAP) Revenue by Players (2019-2024)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2019-2024)
3.2 Global CD47 (IAP) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CD47 (IAP) BY REGIONS
4.1 CD47 (IAP) Market Size by Regions (2019-2024)
4.2 Americas CD47 (IAP) Market Size Growth (2019-2024)
4.3 APAC CD47 (IAP) Market Size Growth (2019-2024)
4.4 Europe CD47 (IAP) Market Size Growth (2019-2024)
4.5 Middle East & Africa CD47 (IAP) Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas CD47 (IAP) Market Size by Country (2019-2024)
5.2 Americas CD47 (IAP) Market Size by Type (2019-2024)
5.3 Americas CD47 (IAP) Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD47 (IAP) Market Size by Region (2019-2024)
6.2 APAC CD47 (IAP) Market Size by Type (2019-2024)
6.3 APAC CD47 (IAP) Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CD47 (IAP) by Country (2019-2024)
7.2 Europe CD47 (IAP) Market Size by Type (2019-2024)
7.3 Europe CD47 (IAP) Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD47 (IAP) by Region (2019-2024)
8.2 Middle East & Africa CD47 (IAP) Market Size by Type (2019-2024)
8.3 Middle East & Africa CD47 (IAP) Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CD47 (IAP) MARKET FORECAST
10.1 Global CD47 (IAP) Forecast by Regions (2025-2030)
10.1.1 Global CD47 (IAP) Forecast by Regions (2025-2030)
10.1.2 Americas CD47 (IAP) Forecast
10.1.3 APAC CD47 (IAP) Forecast
10.1.4 Europe CD47 (IAP) Forecast
10.1.5 Middle East & Africa CD47 (IAP) Forecast
10.2 Americas CD47 (IAP) Forecast by Country (2025-2030)
10.2.1 United States CD47 (IAP) Market Forecast
10.2.2 Canada CD47 (IAP) Market Forecast
10.2.3 Mexico CD47 (IAP) Market Forecast
10.2.4 Brazil CD47 (IAP) Market Forecast
10.3 APAC CD47 (IAP) Forecast by Region (2025-2030)
10.3.1 China CD47 (IAP) Market Forecast
10.3.2 Japan CD47 (IAP) Market Forecast
10.3.3 Korea CD47 (IAP) Market Forecast
10.3.4 Southeast Asia CD47 (IAP) Market Forecast
10.3.5 India CD47 (IAP) Market Forecast
10.3.6 Australia CD47 (IAP) Market Forecast
10.4 Europe CD47 (IAP) Forecast by Country (2025-2030)
10.4.1 Germany CD47 (IAP) Market Forecast
10.4.2 France CD47 (IAP) Market Forecast
10.4.3 UK CD47 (IAP) Market Forecast
10.4.4 Italy CD47 (IAP) Market Forecast
10.4.5 Russia CD47 (IAP) Market Forecast
10.5 Middle East & Africa CD47 (IAP) Forecast by Region (2025-2030)
10.5.1 Egypt CD47 (IAP) Market Forecast
10.5.2 South Africa CD47 (IAP) Market Forecast
10.5.3 Israel CD47 (IAP) Market Forecast
10.5.4 Turkey CD47 (IAP) Market Forecast
10.5.5 GCC Countries CD47 (IAP) Market Forecast
10.6 Global CD47 (IAP) Forecast by Type (2025-2030)
10.7 Global CD47 (IAP) Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Gilead
11.1.1 Gilead Company Information
11.1.2 Gilead CD47 (IAP) Product Offered
11.1.3 Gilead CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Gilead Main Business Overview
11.1.5 Gilead Latest Developments
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Information
11.2.2 Innovent Biologics CD47 (IAP) Product Offered
11.2.3 Innovent Biologics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Innovent Biologics Main Business Overview
11.2.5 Innovent Biologics Latest Developments
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Information
11.3.2 Akeso, Inc CD47 (IAP) Product Offered
11.3.3 Akeso, Inc CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Akeso, Inc Main Business Overview
11.3.5 Akeso, Inc Latest Developments
11.4 Arch Oncology
11.4.1 Arch Oncology Company Information
11.4.2 Arch Oncology CD47 (IAP) Product Offered
11.4.3 Arch Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Arch Oncology Main Business Overview
11.4.5 Arch Oncology Latest Developments
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Information
11.5.2 ImmuneOncia Therapeutics CD47 (IAP) Product Offered
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 ImmuneOncia Therapeutics Main Business Overview
11.5.5 ImmuneOncia Therapeutics Latest Developments
11.6 I-MAB
11.6.1 I-MAB Company Information
11.6.2 I-MAB CD47 (IAP) Product Offered
11.6.3 I-MAB CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 I-MAB Main Business Overview
11.6.5 I-MAB Latest Developments
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Information
11.7.2 Sorrento Therapeutics CD47 (IAP) Product Offered
11.7.3 Sorrento Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Sorrento Therapeutics Main Business Overview
11.7.5 Sorrento Therapeutics Latest Developments
11.8 Zai Lab
11.8.1 Zai Lab Company Information
11.8.2 Zai Lab CD47 (IAP) Product Offered
11.8.3 Zai Lab CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Zai Lab Main Business Overview
11.8.5 Zai Lab Latest Developments
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Information
11.9.2 ImmuneOnco CD47 (IAP) Product Offered
11.9.3 ImmuneOnco CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 ImmuneOnco Main Business Overview
11.9.5 ImmuneOnco Latest Developments
11.10 Hengrui
11.10.1 Hengrui Company Information
11.10.2 Hengrui CD47 (IAP) Product Offered
11.10.3 Hengrui CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Hengrui Main Business Overview
11.10.5 Hengrui Latest Developments
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Information
11.11.2 Beijing Mab-works CD47 (IAP) Product Offered
11.11.3 Beijing Mab-works CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Beijing Mab-works Main Business Overview
11.11.5 Beijing Mab-works Latest Developments
11.12 Hanxbio
11.12.1 Hanxbio Company Information
11.12.2 Hanxbio CD47 (IAP) Product Offered
11.12.3 Hanxbio CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Hanxbio Main Business Overview
11.12.5 Hanxbio Latest Developments
11.13 ALX Oncology
11.13.1 ALX Oncology Company Information
11.13.2 ALX Oncology CD47 (IAP) Product Offered
11.13.3 ALX Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 ALX Oncology Main Business Overview
11.13.5 ALX Oncology Latest Developments
11.14 Surface Oncology
11.14.1 Surface Oncology Company Information
11.14.2 Surface Oncology CD47 (IAP) Product Offered
11.14.3 Surface Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Surface Oncology Main Business Overview
11.14.5 Surface Oncology Latest Developments
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Information
11.15.2 TG Therapeutics CD47 (IAP) Product Offered
11.15.3 TG Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 TG Therapeutics Main Business Overview
11.15.5 TG Therapeutics Latest Developments
11.16 EpicentRx
11.16.1 EpicentRx Company Information
11.16.2 EpicentRx CD47 (IAP) Product Offered
11.16.3 EpicentRx CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 EpicentRx Main Business Overview
11.16.5 EpicentRx Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CD47 (IAP) Market Size 2019-2030
2.1.2 CD47 (IAP) Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 CD47 (IAP) Segment by Type
2.2.1 CD47 Monoclonal Antibody
2.2.2 CD47 Double Antibody
2.2.3 CD47 Fusion Protein
2.3 CD47 (IAP) Market Size by Type
2.3.1 CD47 (IAP) Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global CD47 (IAP) Market Size Market Share by Type (2019-2024)
2.4 CD47 (IAP) Segment by Application
2.4.1 Solid Tumor
2.4.2 Lymphoma
2.4.3 Others
2.5 CD47 (IAP) Market Size by Application
2.5.1 CD47 (IAP) Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global CD47 (IAP) Market Size Market Share by Application (2019-2024)
3 CD47 (IAP) MARKET SIZE BY PLAYER
3.1 CD47 (IAP) Market Size Market Share by Players
3.1.1 Global CD47 (IAP) Revenue by Players (2019-2024)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2019-2024)
3.2 Global CD47 (IAP) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CD47 (IAP) BY REGIONS
4.1 CD47 (IAP) Market Size by Regions (2019-2024)
4.2 Americas CD47 (IAP) Market Size Growth (2019-2024)
4.3 APAC CD47 (IAP) Market Size Growth (2019-2024)
4.4 Europe CD47 (IAP) Market Size Growth (2019-2024)
4.5 Middle East & Africa CD47 (IAP) Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas CD47 (IAP) Market Size by Country (2019-2024)
5.2 Americas CD47 (IAP) Market Size by Type (2019-2024)
5.3 Americas CD47 (IAP) Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD47 (IAP) Market Size by Region (2019-2024)
6.2 APAC CD47 (IAP) Market Size by Type (2019-2024)
6.3 APAC CD47 (IAP) Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe CD47 (IAP) by Country (2019-2024)
7.2 Europe CD47 (IAP) Market Size by Type (2019-2024)
7.3 Europe CD47 (IAP) Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CD47 (IAP) by Region (2019-2024)
8.2 Middle East & Africa CD47 (IAP) Market Size by Type (2019-2024)
8.3 Middle East & Africa CD47 (IAP) Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CD47 (IAP) MARKET FORECAST
10.1 Global CD47 (IAP) Forecast by Regions (2025-2030)
10.1.1 Global CD47 (IAP) Forecast by Regions (2025-2030)
10.1.2 Americas CD47 (IAP) Forecast
10.1.3 APAC CD47 (IAP) Forecast
10.1.4 Europe CD47 (IAP) Forecast
10.1.5 Middle East & Africa CD47 (IAP) Forecast
10.2 Americas CD47 (IAP) Forecast by Country (2025-2030)
10.2.1 United States CD47 (IAP) Market Forecast
10.2.2 Canada CD47 (IAP) Market Forecast
10.2.3 Mexico CD47 (IAP) Market Forecast
10.2.4 Brazil CD47 (IAP) Market Forecast
10.3 APAC CD47 (IAP) Forecast by Region (2025-2030)
10.3.1 China CD47 (IAP) Market Forecast
10.3.2 Japan CD47 (IAP) Market Forecast
10.3.3 Korea CD47 (IAP) Market Forecast
10.3.4 Southeast Asia CD47 (IAP) Market Forecast
10.3.5 India CD47 (IAP) Market Forecast
10.3.6 Australia CD47 (IAP) Market Forecast
10.4 Europe CD47 (IAP) Forecast by Country (2025-2030)
10.4.1 Germany CD47 (IAP) Market Forecast
10.4.2 France CD47 (IAP) Market Forecast
10.4.3 UK CD47 (IAP) Market Forecast
10.4.4 Italy CD47 (IAP) Market Forecast
10.4.5 Russia CD47 (IAP) Market Forecast
10.5 Middle East & Africa CD47 (IAP) Forecast by Region (2025-2030)
10.5.1 Egypt CD47 (IAP) Market Forecast
10.5.2 South Africa CD47 (IAP) Market Forecast
10.5.3 Israel CD47 (IAP) Market Forecast
10.5.4 Turkey CD47 (IAP) Market Forecast
10.5.5 GCC Countries CD47 (IAP) Market Forecast
10.6 Global CD47 (IAP) Forecast by Type (2025-2030)
10.7 Global CD47 (IAP) Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Gilead
11.1.1 Gilead Company Information
11.1.2 Gilead CD47 (IAP) Product Offered
11.1.3 Gilead CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Gilead Main Business Overview
11.1.5 Gilead Latest Developments
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Information
11.2.2 Innovent Biologics CD47 (IAP) Product Offered
11.2.3 Innovent Biologics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Innovent Biologics Main Business Overview
11.2.5 Innovent Biologics Latest Developments
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Information
11.3.2 Akeso, Inc CD47 (IAP) Product Offered
11.3.3 Akeso, Inc CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Akeso, Inc Main Business Overview
11.3.5 Akeso, Inc Latest Developments
11.4 Arch Oncology
11.4.1 Arch Oncology Company Information
11.4.2 Arch Oncology CD47 (IAP) Product Offered
11.4.3 Arch Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Arch Oncology Main Business Overview
11.4.5 Arch Oncology Latest Developments
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Information
11.5.2 ImmuneOncia Therapeutics CD47 (IAP) Product Offered
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 ImmuneOncia Therapeutics Main Business Overview
11.5.5 ImmuneOncia Therapeutics Latest Developments
11.6 I-MAB
11.6.1 I-MAB Company Information
11.6.2 I-MAB CD47 (IAP) Product Offered
11.6.3 I-MAB CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 I-MAB Main Business Overview
11.6.5 I-MAB Latest Developments
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Information
11.7.2 Sorrento Therapeutics CD47 (IAP) Product Offered
11.7.3 Sorrento Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Sorrento Therapeutics Main Business Overview
11.7.5 Sorrento Therapeutics Latest Developments
11.8 Zai Lab
11.8.1 Zai Lab Company Information
11.8.2 Zai Lab CD47 (IAP) Product Offered
11.8.3 Zai Lab CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Zai Lab Main Business Overview
11.8.5 Zai Lab Latest Developments
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Information
11.9.2 ImmuneOnco CD47 (IAP) Product Offered
11.9.3 ImmuneOnco CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 ImmuneOnco Main Business Overview
11.9.5 ImmuneOnco Latest Developments
11.10 Hengrui
11.10.1 Hengrui Company Information
11.10.2 Hengrui CD47 (IAP) Product Offered
11.10.3 Hengrui CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Hengrui Main Business Overview
11.10.5 Hengrui Latest Developments
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Information
11.11.2 Beijing Mab-works CD47 (IAP) Product Offered
11.11.3 Beijing Mab-works CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Beijing Mab-works Main Business Overview
11.11.5 Beijing Mab-works Latest Developments
11.12 Hanxbio
11.12.1 Hanxbio Company Information
11.12.2 Hanxbio CD47 (IAP) Product Offered
11.12.3 Hanxbio CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Hanxbio Main Business Overview
11.12.5 Hanxbio Latest Developments
11.13 ALX Oncology
11.13.1 ALX Oncology Company Information
11.13.2 ALX Oncology CD47 (IAP) Product Offered
11.13.3 ALX Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 ALX Oncology Main Business Overview
11.13.5 ALX Oncology Latest Developments
11.14 Surface Oncology
11.14.1 Surface Oncology Company Information
11.14.2 Surface Oncology CD47 (IAP) Product Offered
11.14.3 Surface Oncology CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Surface Oncology Main Business Overview
11.14.5 Surface Oncology Latest Developments
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Information
11.15.2 TG Therapeutics CD47 (IAP) Product Offered
11.15.3 TG Therapeutics CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 TG Therapeutics Main Business Overview
11.15.5 TG Therapeutics Latest Developments
11.16 EpicentRx
11.16.1 EpicentRx Company Information
11.16.2 EpicentRx CD47 (IAP) Product Offered
11.16.3 EpicentRx CD47 (IAP) Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 EpicentRx Main Business Overview
11.16.5 EpicentRx Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. CD47 (IAP) Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of CD47 Monoclonal Antibody
Table 3. Major Players of CD47 Double Antibody
Table 4. Major Players of CD47 Fusion Protein
Table 5. CD47 (IAP) Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 6. Global CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 7. Global CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 8. CD47 (IAP) Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 10. Global CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 11. Global CD47 (IAP) Revenue by Players (2019-2024) & ($ Millions)
Table 12. Global CD47 (IAP) Revenue Market Share by Player (2019-2024)
Table 13. CD47 (IAP) Key Players Head office and Products Offered
Table 14. CD47 (IAP) Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global CD47 (IAP) Market Size by Regions 2019-2024 & ($ Millions)
Table 18. Global CD47 (IAP) Market Size Market Share by Regions (2019-2024)
Table 19. Global CD47 (IAP) Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global CD47 (IAP) Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas CD47 (IAP) Market Size by Country (2019-2024) & ($ Millions)
Table 22. Americas CD47 (IAP) Market Size Market Share by Country (2019-2024)
Table 23. Americas CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 24. Americas CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 25. Americas CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 26. Americas CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 27. APAC CD47 (IAP) Market Size by Region (2019-2024) & ($ Millions)
Table 28. APAC CD47 (IAP) Market Size Market Share by Region (2019-2024)
Table 29. APAC CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 30. APAC CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 31. APAC CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 32. APAC CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 33. Europe CD47 (IAP) Market Size by Country (2019-2024) & ($ Millions)
Table 34. Europe CD47 (IAP) Market Size Market Share by Country (2019-2024)
Table 35. Europe CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 36. Europe CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 37. Europe CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 38. Europe CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 39. Middle East & Africa CD47 (IAP) Market Size by Region (2019-2024) & ($ Millions)
Table 40. Middle East & Africa CD47 (IAP) Market Size Market Share by Region (2019-2024)
Table 41. Middle East & Africa CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 42. Middle East & Africa CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 43. Middle East & Africa CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 44. Middle East & Africa CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 45. Key Market Drivers & Growth Opportunities of CD47 (IAP)
Table 46. Key Market Challenges & Risks of CD47 (IAP)
Table 47. Key Industry Trends of CD47 (IAP)
Table 48. Global CD47 (IAP) Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 49. Global CD47 (IAP) Market Size Market Share Forecast by Regions (2025-2030)
Table 50. Global CD47 (IAP) Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 51. Global CD47 (IAP) Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 52. Gilead Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 53. Gilead CD47 (IAP) Product Offered
Table 54. Gilead CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Gilead Main Business
Table 56. Gilead Latest Developments
Table 57. Innovent Biologics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 58. Innovent Biologics CD47 (IAP) Product Offered
Table 59. Innovent Biologics Main Business
Table 60. Innovent Biologics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. Innovent Biologics Latest Developments
Table 62. Akeso, Inc Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 63. Akeso, Inc CD47 (IAP) Product Offered
Table 64. Akeso, Inc Main Business
Table 65. Akeso, Inc CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Akeso, Inc Latest Developments
Table 67. Arch Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 68. Arch Oncology CD47 (IAP) Product Offered
Table 69. Arch Oncology Main Business
Table 70. Arch Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Arch Oncology Latest Developments
Table 72. ImmuneOncia Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 73. ImmuneOncia Therapeutics CD47 (IAP) Product Offered
Table 74. ImmuneOncia Therapeutics Main Business
Table 75. ImmuneOncia Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. ImmuneOncia Therapeutics Latest Developments
Table 77. I-MAB Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 78. I-MAB CD47 (IAP) Product Offered
Table 79. I-MAB Main Business
Table 80. I-MAB CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. I-MAB Latest Developments
Table 82. Sorrento Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 83. Sorrento Therapeutics CD47 (IAP) Product Offered
Table 84. Sorrento Therapeutics Main Business
Table 85. Sorrento Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Sorrento Therapeutics Latest Developments
Table 87. Zai Lab Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 88. Zai Lab CD47 (IAP) Product Offered
Table 89. Zai Lab Main Business
Table 90. Zai Lab CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Zai Lab Latest Developments
Table 92. ImmuneOnco Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 93. ImmuneOnco CD47 (IAP) Product Offered
Table 94. ImmuneOnco Main Business
Table 95. ImmuneOnco CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. ImmuneOnco Latest Developments
Table 97. Hengrui Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 98. Hengrui CD47 (IAP) Product Offered
Table 99. Hengrui Main Business
Table 100. Hengrui CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Hengrui Latest Developments
Table 102. Beijing Mab-works Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 103. Beijing Mab-works CD47 (IAP) Product Offered
Table 104. Beijing Mab-works CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 105. Beijing Mab-works Main Business
Table 106. Beijing Mab-works Latest Developments
Table 107. Hanxbio Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 108. Hanxbio CD47 (IAP) Product Offered
Table 109. Hanxbio Main Business
Table 110. Hanxbio CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Hanxbio Latest Developments
Table 112. ALX Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 113. ALX Oncology CD47 (IAP) Product Offered
Table 114. ALX Oncology Main Business
Table 115. ALX Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. ALX Oncology Latest Developments
Table 117. Surface Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 118. Surface Oncology CD47 (IAP) Product Offered
Table 119. Surface Oncology Main Business
Table 120. Surface Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Surface Oncology Latest Developments
Table 122. TG Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 123. TG Therapeutics CD47 (IAP) Product Offered
Table 124. TG Therapeutics Main Business
Table 125. TG Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 126. TG Therapeutics Latest Developments
Table 127. EpicentRx Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 128. EpicentRx CD47 (IAP) Product Offered
Table 129. EpicentRx Main Business
Table 130. EpicentRx CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 131. EpicentRx Latest Developments
Table 1. CD47 (IAP) Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of CD47 Monoclonal Antibody
Table 3. Major Players of CD47 Double Antibody
Table 4. Major Players of CD47 Fusion Protein
Table 5. CD47 (IAP) Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 6. Global CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 7. Global CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 8. CD47 (IAP) Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 10. Global CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 11. Global CD47 (IAP) Revenue by Players (2019-2024) & ($ Millions)
Table 12. Global CD47 (IAP) Revenue Market Share by Player (2019-2024)
Table 13. CD47 (IAP) Key Players Head office and Products Offered
Table 14. CD47 (IAP) Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global CD47 (IAP) Market Size by Regions 2019-2024 & ($ Millions)
Table 18. Global CD47 (IAP) Market Size Market Share by Regions (2019-2024)
Table 19. Global CD47 (IAP) Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global CD47 (IAP) Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas CD47 (IAP) Market Size by Country (2019-2024) & ($ Millions)
Table 22. Americas CD47 (IAP) Market Size Market Share by Country (2019-2024)
Table 23. Americas CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 24. Americas CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 25. Americas CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 26. Americas CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 27. APAC CD47 (IAP) Market Size by Region (2019-2024) & ($ Millions)
Table 28. APAC CD47 (IAP) Market Size Market Share by Region (2019-2024)
Table 29. APAC CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 30. APAC CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 31. APAC CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 32. APAC CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 33. Europe CD47 (IAP) Market Size by Country (2019-2024) & ($ Millions)
Table 34. Europe CD47 (IAP) Market Size Market Share by Country (2019-2024)
Table 35. Europe CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 36. Europe CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 37. Europe CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 38. Europe CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 39. Middle East & Africa CD47 (IAP) Market Size by Region (2019-2024) & ($ Millions)
Table 40. Middle East & Africa CD47 (IAP) Market Size Market Share by Region (2019-2024)
Table 41. Middle East & Africa CD47 (IAP) Market Size by Type (2019-2024) & ($ Millions)
Table 42. Middle East & Africa CD47 (IAP) Market Size Market Share by Type (2019-2024)
Table 43. Middle East & Africa CD47 (IAP) Market Size by Application (2019-2024) & ($ Millions)
Table 44. Middle East & Africa CD47 (IAP) Market Size Market Share by Application (2019-2024)
Table 45. Key Market Drivers & Growth Opportunities of CD47 (IAP)
Table 46. Key Market Challenges & Risks of CD47 (IAP)
Table 47. Key Industry Trends of CD47 (IAP)
Table 48. Global CD47 (IAP) Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 49. Global CD47 (IAP) Market Size Market Share Forecast by Regions (2025-2030)
Table 50. Global CD47 (IAP) Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 51. Global CD47 (IAP) Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 52. Gilead Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 53. Gilead CD47 (IAP) Product Offered
Table 54. Gilead CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Gilead Main Business
Table 56. Gilead Latest Developments
Table 57. Innovent Biologics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 58. Innovent Biologics CD47 (IAP) Product Offered
Table 59. Innovent Biologics Main Business
Table 60. Innovent Biologics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. Innovent Biologics Latest Developments
Table 62. Akeso, Inc Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 63. Akeso, Inc CD47 (IAP) Product Offered
Table 64. Akeso, Inc Main Business
Table 65. Akeso, Inc CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Akeso, Inc Latest Developments
Table 67. Arch Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 68. Arch Oncology CD47 (IAP) Product Offered
Table 69. Arch Oncology Main Business
Table 70. Arch Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Arch Oncology Latest Developments
Table 72. ImmuneOncia Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 73. ImmuneOncia Therapeutics CD47 (IAP) Product Offered
Table 74. ImmuneOncia Therapeutics Main Business
Table 75. ImmuneOncia Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. ImmuneOncia Therapeutics Latest Developments
Table 77. I-MAB Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 78. I-MAB CD47 (IAP) Product Offered
Table 79. I-MAB Main Business
Table 80. I-MAB CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. I-MAB Latest Developments
Table 82. Sorrento Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 83. Sorrento Therapeutics CD47 (IAP) Product Offered
Table 84. Sorrento Therapeutics Main Business
Table 85. Sorrento Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Sorrento Therapeutics Latest Developments
Table 87. Zai Lab Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 88. Zai Lab CD47 (IAP) Product Offered
Table 89. Zai Lab Main Business
Table 90. Zai Lab CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Zai Lab Latest Developments
Table 92. ImmuneOnco Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 93. ImmuneOnco CD47 (IAP) Product Offered
Table 94. ImmuneOnco Main Business
Table 95. ImmuneOnco CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. ImmuneOnco Latest Developments
Table 97. Hengrui Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 98. Hengrui CD47 (IAP) Product Offered
Table 99. Hengrui Main Business
Table 100. Hengrui CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Hengrui Latest Developments
Table 102. Beijing Mab-works Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 103. Beijing Mab-works CD47 (IAP) Product Offered
Table 104. Beijing Mab-works CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 105. Beijing Mab-works Main Business
Table 106. Beijing Mab-works Latest Developments
Table 107. Hanxbio Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 108. Hanxbio CD47 (IAP) Product Offered
Table 109. Hanxbio Main Business
Table 110. Hanxbio CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Hanxbio Latest Developments
Table 112. ALX Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 113. ALX Oncology CD47 (IAP) Product Offered
Table 114. ALX Oncology Main Business
Table 115. ALX Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. ALX Oncology Latest Developments
Table 117. Surface Oncology Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 118. Surface Oncology CD47 (IAP) Product Offered
Table 119. Surface Oncology Main Business
Table 120. Surface Oncology CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Surface Oncology Latest Developments
Table 122. TG Therapeutics Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 123. TG Therapeutics CD47 (IAP) Product Offered
Table 124. TG Therapeutics Main Business
Table 125. TG Therapeutics CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 126. TG Therapeutics Latest Developments
Table 127. EpicentRx Details, Company Type, CD47 (IAP) Area Served and Its Competitors
Table 128. EpicentRx CD47 (IAP) Product Offered
Table 129. EpicentRx Main Business
Table 130. EpicentRx CD47 (IAP) Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 131. EpicentRx Latest Developments
LIST OF FIGURES
Figure 1. CD47 (IAP) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CD47 (IAP) Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. CD47 (IAP) Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. CD47 (IAP) Sales Market Share by Country/Region (2023)
Figure 8. CD47 (IAP) Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global CD47 (IAP) Market Size Market Share by Type in 2023
Figure 10. CD47 (IAP) in Solid Tumor
Figure 11. Global CD47 (IAP) Market: Solid Tumor (2019-2024) & ($ Millions)
Figure 12. CD47 (IAP) in Lymphoma
Figure 13. Global CD47 (IAP) Market: Lymphoma (2019-2024) & ($ Millions)
Figure 14. CD47 (IAP) in Others
Figure 15. Global CD47 (IAP) Market: Others (2019-2024) & ($ Millions)
Figure 16. Global CD47 (IAP) Market Size Market Share by Application in 2023
Figure 17. Global CD47 (IAP) Revenue Market Share by Player in 2023
Figure 18. Global CD47 (IAP) Market Size Market Share by Regions (2019-2024)
Figure 19. Americas CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 20. APAC CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 21. Europe CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 23. Americas CD47 (IAP) Value Market Share by Country in 2023
Figure 24. United States CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC CD47 (IAP) Market Size Market Share by Region in 2023
Figure 29. APAC CD47 (IAP) Market Size Market Share by Type in 2023
Figure 30. APAC CD47 (IAP) Market Size Market Share by Application in 2023
Figure 31. China CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 35. India CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe CD47 (IAP) Market Size Market Share by Country in 2023
Figure 38. Europe CD47 (IAP) Market Size Market Share by Type (2019-2024)
Figure 39. Europe CD47 (IAP) Market Size Market Share by Application (2019-2024)
Figure 40. Germany CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 41. France CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa CD47 (IAP) Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa CD47 (IAP) Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa CD47 (IAP) Market Size Market Share by Application (2019-2024)
Figure 48. Egypt CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 54. APAC CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 55. Europe CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 57. United States CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 58. Canada CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 59. Mexico CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 60. Brazil CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 61. China CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 62. Japan CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 63. Korea CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 65. India CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 66. Australia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 67. Germany CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 68. France CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 69. UK CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 70. Italy CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 71. Russia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 72. Spain CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 73. Egypt CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 74. South Africa CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 75. Israel CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 76. Turkey CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 78. Global CD47 (IAP) Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global CD47 (IAP) Market Size Market Share Forecast by Application (2025-2030)
Figure 1. CD47 (IAP) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global CD47 (IAP) Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. CD47 (IAP) Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. CD47 (IAP) Sales Market Share by Country/Region (2023)
Figure 8. CD47 (IAP) Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global CD47 (IAP) Market Size Market Share by Type in 2023
Figure 10. CD47 (IAP) in Solid Tumor
Figure 11. Global CD47 (IAP) Market: Solid Tumor (2019-2024) & ($ Millions)
Figure 12. CD47 (IAP) in Lymphoma
Figure 13. Global CD47 (IAP) Market: Lymphoma (2019-2024) & ($ Millions)
Figure 14. CD47 (IAP) in Others
Figure 15. Global CD47 (IAP) Market: Others (2019-2024) & ($ Millions)
Figure 16. Global CD47 (IAP) Market Size Market Share by Application in 2023
Figure 17. Global CD47 (IAP) Revenue Market Share by Player in 2023
Figure 18. Global CD47 (IAP) Market Size Market Share by Regions (2019-2024)
Figure 19. Americas CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 20. APAC CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 21. Europe CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa CD47 (IAP) Market Size 2019-2024 ($ Millions)
Figure 23. Americas CD47 (IAP) Value Market Share by Country in 2023
Figure 24. United States CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC CD47 (IAP) Market Size Market Share by Region in 2023
Figure 29. APAC CD47 (IAP) Market Size Market Share by Type in 2023
Figure 30. APAC CD47 (IAP) Market Size Market Share by Application in 2023
Figure 31. China CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 35. India CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe CD47 (IAP) Market Size Market Share by Country in 2023
Figure 38. Europe CD47 (IAP) Market Size Market Share by Type (2019-2024)
Figure 39. Europe CD47 (IAP) Market Size Market Share by Application (2019-2024)
Figure 40. Germany CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 41. France CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa CD47 (IAP) Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa CD47 (IAP) Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa CD47 (IAP) Market Size Market Share by Application (2019-2024)
Figure 48. Egypt CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country CD47 (IAP) Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 54. APAC CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 55. Europe CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 57. United States CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 58. Canada CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 59. Mexico CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 60. Brazil CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 61. China CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 62. Japan CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 63. Korea CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 65. India CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 66. Australia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 67. Germany CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 68. France CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 69. UK CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 70. Italy CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 71. Russia CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 72. Spain CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 73. Egypt CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 74. South Africa CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 75. Israel CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 76. Turkey CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries CD47 (IAP) Market Size 2025-2030 ($ Millions)
Figure 78. Global CD47 (IAP) Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global CD47 (IAP) Market Size Market Share Forecast by Application (2025-2030)
